Anti-IL21 (NN8828)

:Inflammation - Rheumatoid arthritis
:Phase 2

A recombinant human monoclonal antibody. The compound’s novel mechanism of action is intended to improve treatment outcomes in patients who do not respond adequately to existing treatments. A phase 2a programme is ongoing.

Company announcements
No company announcements matching the search criteria
 

Press releases
No press releases matching the search criteria
 

Scientific abstracts

No scientific abstracts matching the search criteria


You can search for more clinical trials on http://clinicaltrials.gov
  •